{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:57Z","timestamp":1786997937202,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Ministry of Health"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.10.049","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T01:16:28Z","timestamp":1478222188000},"page":"6309-6315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination"],"prefix":"10.1016","volume":"34","author":[{"given":"Mari\u00ebtte B.","family":"van Ravenhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Bonacic","family":"Marinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne P.","family":"Stoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.10.049_b0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.049_b0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jinf.2015.02.006","article-title":"Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy","volume":"71","author":"Jeppesen","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.10.049_b0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1473-3099(14)70806-0","article-title":"Epidemiology of invasive meningococcal disease in the Netherlands, 1960\u20132012: an analysis of national surveillance data","volume":"14","author":"Bijlsma","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.10.049_b0035","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.049_b0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.10.049_b0045","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.049_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0055","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.049_b0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2016.10.049_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.049_b0075","doi-asserted-by":"crossref","first-page":"e100651","DOI":"10.1371\/journal.pone.0100651","article-title":"Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers","volume":"9","author":"Stoof","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.049_b0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.10.049_b0085","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.049_b0090","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.10.049_b0095","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.10.049_b0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/CVI.00364-08","article-title":"Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay","volume":"16","author":"de Voer","year":"2009","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2016.10.049_b0105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"de Voer","year":"2008","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2016.10.049_b0110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/CDLI.11.2.272-279.2004","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.10.049_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.epidem.2014.08.002","article-title":"A two-phase within-host model for immune response and its application to serological profiles of pertussis","volume":"9","author":"de Graaf","year":"2014","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2016.10.049_b0120","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1016\/j.vaccine.2013.05.073","article-title":"A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens","volume":"31","author":"Berbers","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.049_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.epidem.2016.04.001","article-title":"Linking the seroresponse to infection to within-host heterogeneity in antibody production","volume":"16","author":"Teunis","year":"2016","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2016.10.049_b0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-202561","article-title":"Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study","volume":"73","author":"Stoof","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.10.049_b0140","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C","article-title":"Improved confidence intervals for the difference between binomial proportions based on paired data","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2016.10.049_b0145","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/INF.0b013e318224fb14","article-title":"Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine","volume":"30","author":"de Whalley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0150","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.10.049_b0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/infdis\/169.4.847","article-title":"Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel","volume":"169","author":"Zangwill","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0160","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/INF.0b013e3180cc2c25","article-title":"Reconsideration of the use of meningococcal polysaccharide vaccine","volume":"26","author":"Granoff","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CDLI.11.1.83-88.2004","article-title":"Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A\/C polysaccharide vaccination in Saudi Arabia","volume":"11","author":"Jokhdar","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.10.049_b0170","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination","volume":"98","author":"de Whalley","year":"2013","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2016.10.049_b0175","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.10.049_b0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e3181f728fd","article-title":"Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial","volume":"30","author":"Khatami","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0185","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/INF.0b013e3181d9e653","article-title":"Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0190","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/INF.0b013e31824f34e6","article-title":"Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom","volume":"31","author":"Findlow","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.10.049_b0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.049_b0200","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.28206","article-title":"Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012","volume":"10","author":"Broker","year":"2014","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2016.10.049_b0205","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in Endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.10.049_b0210","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.28.21188","article-title":"Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015","volume":"20","author":"Campbell","year":"2015","journal-title":"Euro Surveill: bulletin Europeen sur les maladies transmissibles = Eur Communicable Dis Bull"},{"key":"10.1016\/j.vaccine.2016.10.049_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1201622","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","author":"Baxter","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2016.10.049_b0220","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T23:48:54Z","timestamp":1601164134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":44,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16309847"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}